NCT05112848 (COVID-19) is a Phase 2 clinical trial of NVX-CoV2373 in SARS-CoV-2 Infection, sponsored by Novavax.

Who is sponsoring NCT05112848?

NCT05112848 is sponsored by Novavax.

What drugs are being tested in NCT05112848?

Interventions in NCT05112848: NVX-CoV2373.

What condition does NCT05112848 study?

NCT05112848 studies SARS-CoV-2 Infection.

Is NCT05112848 still recruiting?

NCT05112848 is currently completed. Last updated 16 March 2023.

Last reviewed 2023-03-16 · How we verify

NCT05112848: COVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)

Completed Phase 2 Last updated 16 March 2023

What this trial tests

Phase 2 trial testing NVX-CoV2373 in SARS-CoV-2 Infection in 384 participants. Completed in 30 November 2022.

Timeline

28 February 2022

Primary endpoint
23 May 2022

30 November 2022

Quick facts

Lead sponsor	Novavax
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	384
Start date	28 February 2022
Primary completion	23 May 2022
Estimated completion	30 November 2022
Sites	7 locations across South Africa

Drugs / interventions tested

NVX-CoV2373 — full drug profile →

Conditions studied

SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →

Sponsor

Novavax — full company profile →

Who can join

Adults 18 to 65, any sex, with SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2, randomized, observer-blinded study evaluating the safety and immunogenicity of SARS-CoV-2 with Matrix-M™ Adjuvant in people living with human immunodeficiency virus (HIV) (PLWH) and HIV- negative adults, seronegative to SARS-CoV-2 at baseline.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.
Huang Y, Guo X, Wu Y, Chen X, et al · · 2024 · cited 188× · PMID 38378653 · DOI 10.1038/s41392-024-01745-z
Targeted modulation of immune cells and tissues using engineered biomaterials.
Yousefpour P, Ni K, Irvine DJ. · · 2023 · cited 105× · PMID 37772035 · DOI 10.1038/s44222-022-00016-2
Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.
Zhou H, Ni WJ, Huang W, Wang Z, et al · · 2022 · cited 12× · PMID 35450063 · DOI 10.3389/fimmu.2022.834942
Enhancing vaccine effectiveness in the elderly to counter antibiotic resistance: The potential of adjuvants via pattern recognition receptors.
Jung M, Kim H, Choi E, Shin MK, et al · · 2024 · cited 1× · PMID 39693178 · DOI 10.1080/21645515.2024.2317439
Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial.
Bennett C, Hoosain Z, Koen A, Lalloo U, et al · · 2024 · cited 1× · PMID 39343247 · DOI 10.1016/j.jinf.2024.106285

Verify or expand the search:

Other trials of NVX-CoV2373

Trials testing the same drug.

NCT05875701 — Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines · Phase 3 · completed
NCT05249816 — Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine · Phase 3 · completed
NCT04834869 — COVID-19 Vaccines Safety Tracking (CoVaST) · recruiting

Other recruiting trials for SARS-CoV-2 Infection

Currently open trials in the same condition.

NCT07079670 — Safety and Immunogenicity of NVX-CoV2705 · Phase 3 · active not recruiting
NCT05697068 — Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos · NA · active not recruiting
NCT05172011 — Understanding the Long-term Impact of COVID on Children and Families · active not recruiting
NCT05141058 — T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients · Phase 1 · recruiting
NCT05046470 — SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study · active not recruiting

Other Novavax trials

Trials by the same sponsor.

NCT07086222 — Efficacy and Safety of NVX-CoV2705 · Phase 4 · not yet recruiting
NCT06482359 — Lot Consistency Study of COVID-19 and Influenza Combination Vaccine · Phase 2, PHASE3 · withdrawn
NCT06291857 — A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine · Phase 3 · active not recruiting
NCT06409663 — A Strain Change Study for SARS-CoV-2 rS Vaccines · Phase 3 · completed
NCT06633835 — Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United St · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05112848 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novavax
Last refreshed: 16 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05112848.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing